Invitation: Roche’s Virtual Neurology Investor Event Dienstag, 08. Oktober 2024 - 10:13

Investor Update

Invitation: Roche's Virtual Neurology Investor Event

We are pleased to invite investors and analysts to participate in our virtual event on Thursday, 31 October 2024, to highlight Phase II trontinemab data presented at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Meeting, from 29 October - 1 November 2024.

16:00 - 17:00 CET / 15:00 - 16:00 GMT

11:00 - 12:00 am EDT / 8:00 - 9:00 am PDT

The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 15:00 CET on the day of the event.
> click here

Access to virtual event (pre-registration required)

Please pre-register for our webinar here*.

Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.

A replay of the webcast will be available via > ir.roche.com

*privacy notice

Best regards,

Bruno Eschli Head of Investor Relations	Rishard Salie Investor Relations Officer
Roche Investor Relations
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com

Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com